Inhibitors of diacylglycerol acyltransferase: A review of 2008 patents

Expert Opinion on Therapeutic Patents

Volumn 20, Issue 1, 2010, Pages 19-29

  King, Andrew J ^a   Judd, Andrew S ^a   Souers, Andrew J ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Acyl CoA; Diacylglycerol acyltransferase; Hypertriglyceridemia; Lipids; Obesity; Triglycerides; Type 2 diabetes

Indexed keywords

ACYLTRANSFERASE INHIBITOR; DIACYLGLYCEROL ACYLTRANSFERASE 1 INHIBITOR; FENOFIBRATE; RIMONABANT; SIBUTRAMINE; UNCLASSIFIED DRUG; XANTHOHUMOL;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DRUG INHIBITION; DRUG STRUCTURE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; IC 50; INSULIN RESISTANCE; LIVER FIBROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; BIOLOGICAL PRODUCTS; CARDIOVASCULAR DISEASES; DIACYLGLYCEROL O-ACYLTRANSFERASE; DRUG DELIVERY SYSTEMS; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; HYPERTRIGLYCERIDEMIA; METABOLIC DISEASES; PATENTS AS TOPIC; RISK FACTORS;

EID: 73649126531     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543770903499305     Document Type: Review

References (59)

1. Bansal S, Buring JE, Rifai N, et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007;298(3):309-316
2. Nordestgaard BG, Benn M, Tybjaerg- Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007:298(3):299-308
3. Capeau J. Insulin resistance and steatosis in humans. Diabetes Metab 2008;34 (6 Pt 2):649-657
4. Kennedy EP. Metabolism of lipids. Annu Rev Biochem 1957;26:119-148
5. Kayden HJ, Senior JR, Mattson FH. The monoglyceride pathway of fat absorption in man. J Clin Invest 1967;46(11):1695-1703
6. Yen CL, Stone SJ, Koliwad S, et al. Thematic Review Series: Glycerolipids. DGAT enzymes and triacylglycerol biosynthesis. J Lipid Res 2008;49(11):2283-2301
7. Cases S, Smith SJ, Zheng Y-W, et al. Identification of a gene encoding an acyl CoA:diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis. Proc Natl Acad Sci USA 1998;95(22):13018-13023
8. Cases S, Stone SJ, Zhou P, et al. Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members. J Biol Chem 2001;276(42):38870-38876
9. Smith SJ, Cases S, Jensen DR, et al. Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking DGAT. Nat Genet 2000;25(1):87-90
10. Chen HC, Smith SJ, Ladha Z, et al. Increased insulin and leptin sensitivity in mice lacking acyl CoA:diacylglycerol acyltransferase 1. J Clin Invest 2002;109(8):1049-1055
11. Chen HC, Rao M, Sajan MP, et al. Role of adipocyte-derived factors in enhancing insulin signaling in skeletal muscle and white adipose tissue of mice lacking Acyl CoA:diacylglycerol acyltransferase 1. Diabetes 2004;53(6):1445-1451
12. Chen HC, Ladha Z, Smith SJ, et al. Analysis of energy expenditure at different ambient temperatures in mice lacking DGAT-1. Am J Physiol Endocrinol Metab 2003;284(1):E213-8
13. Buhman KK, Smith SJ, Stone SJ, et al. DGAT-1 is not essential for intestinal triacylglycerol absorption or chylomicron synthesis. J Biol Chem 2002;277(28):25474-25479
14. Bayer. Preparation and use of aryl alkyl acid derivatives for the treatment of obesity. US07091228; 2004
15. Zhao G, Souers AJ, Voorbach M, et al. Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor. J Med Chem 2008;51(3):380-383
16. Birch AM, Birtles S, Buckett LK, et al. Discovery of a potent, selective, and orally efficacious pyrimidinooxazinyl bicyclooctaneacetic acid diacylglycerol acyltransferase-1 inhibitor. J Med Chem 2009;52(6):1558-1568
17. King AJ, Segreti JA, Larson KJ, et al. Diacylglycerol acyltransferase 1 (DGAT-1) inhibition lowers serum triglycerides in the Zucker fatty rat and the hyperlipidemic hamster. J Pharmacol Exp Ther 2009;330(2):526-531
18. Chen HC, Smith SJ, Tow B, et al. Leptin modulates the effects of acyl CoA: diacylglycerol acyltransferase deficiency on murine fur and sebaceous glands. J Clin Invest 2002;109(2):175-181
19. Cases S, Zhou P, Shillingford JM, et al. Development of the mammary gland requires DGAT-1 expression in stromal and epithelial tissues. Development 2004;131(13):3047-3055
20. Chen HC, Farese RV Jr. Inhibition of triglyceride synthesis as a treatment strategy for obesity: lessons from DGAT-1- deficient mice. Arterioscler Thromb Vasc Biol 2005;25(3):482-486
21. Stone SJ, Myers HM, Watkins SM, et al. Lipopenia and skin barrier abnormalities in DGAT2-deficient mice. J Biol Chem 2004;279(12):11767-11776
22. Yu XX, Liu ZX, Morino K, et al. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. Hepatology 2005;42(2):362-371
23. Liu Y, Millar JS, Cromley DA, et al. Knockdown of acyl-CoA:diacylglycerol acyltransferase 2 with antisense oligonucleotide reduces VLDL TG and ApoB secretion in mice. Biochim Biophys Acta 2008;1781(3):97-104
24. Choi CS, Savage DB, Kulkarni A, et al. Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT-1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance. J Biol Chem 2007;282(31):22678-22688
25. Yamaguchi K, Liu Y, McCall S, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007;45(6):1366-1374
26. HubbardBK, GilmoreTA, Serrano-WuMH. Antisense and small-molecule modulation of diacylglycerol acyltransferase. Expert Opin Ther Patent 2007;17:1331-1339
27. Roche. Diacylglycerol acyltransferase inhibitors. WO2006120125; 2006
28. Roche. Diacylglycerol acyltransferase inhibitors. WO2007060140; 2007
29. Roche. Inhibitors of diacylglycerol acyltransferase. WO2006082010; 2006
30. Roche. Diacylglycerol acyltransferase inhibitors. WO2008141976; 2008
31. Takeda. Amide compounds. WO2008011130; 2008
32. Takeda. Amide compounds. WO2008011131; 2008
33. Astrazeneca. Oxadiazole derivatives as DGAT inhibitors. WO2006134317; 2006
34. BMS. Use of thianecarboxamides as DGAT inhbitors. US20080090876; 2008
35. Janssen. Piperidine/piperazine derivatives. WO2008148840; 2008
36. Janssen. Piperidine/piperazine derivatives. WO2008148849; 2008
37. Janssen. Piperidine/piperazine derivatives. WO2008148868; 2008
38. Janssen. Piperidine/piperazine derivatives. WO2008148851; 2008
39. Abbott. Inhibitors of diacyl O-acyltransferase type I enzyme. US2007069112; 2007
40. Abbott. Inhibitors of diacyl O-acyltransferase type I enzyme. US20080015227; 2008
41. Abbott. Inhibitors of diacyl O-acyltransferase type I enzyme. US20080312282; 2008
42. Abbott. Inhibitors of diacyl O-acyltransferase type I enzyme. US20080182861; 2008
43. Abbott. Inhibitors of diacyl O-acyltransferase type I enzyme. US20080293713; 2008
44. Souers AJ, King AJ, Mittelstadt S, et al. "DGAT-1 Inhibitors as Novel Therapeutics for Dyslipidemia" Western Regional ACS meeting, San Diego, 2008
45. Souers AJ. "DGAT-1 Inhibitors as Novel Therapeutics for Dyslipidemia" 237th National ACS meeting, Salt Lake City, 2009
46. Korea Research institute of bioscience and biotechnology. Composition for the prevention and treatment of metabolic disorder containing benzazole derivatives as an active ingredient. WO2008039008; 2008
47. Korea Research institute of bioscience and biotechnology. Indol derivatives, the method for preparing thereof and composition for the prevention and treatment of metabolic disorder containing the same as an active ingredient. WO2008039007; 2008
48. Bioactives. Prenylflavonoid formulations. WO2007016578; 2007
49. Bioactives. Methods and compositions for treating dyslipidemia. WO2008095189; 2008
50. ISIS. Modulation of diacylglycerol acyltransferase 2 expression. WO2004094618; 2004
51. ISIS. Modulation of diacylglycerol acyltransferase 2 expression. US20050272680; 2005
52. ISIS. Compositions and their uses directed to diacylglycerol acyltransferase I. WO2008019351; 2008
53. Tularik and Japan Tobacco. Fused and bicyclic nitrogen-containing heterocycles. WO2004047755; 2004
54. Available from: http://pharma.bayer.com/ scripts/pages/en/news-room/news- room/ archive/newsroom-archive26.php
55. Available from: http://mediaroom.pfizer. com/portal/site/pfizer/index. jsp?ndmViewId=news-view&newsId= 20070827005440&newsLang=en
56. Chia CW, Egan JM. Biology and therapeutic potential of GLP-1 in the treatment of diabetes. Drug Discov Today 2005;2(3):295-301
57. Shih MYS, Kane MA, Zhou P, et al. Retinol esterification by DGAT1 is essential for retinoid homeostasis in murine skin. J Biol Chem 2008;284(7):4292-4299
58. Sankyo. Medicine containing urea derivative. JP2007191471; 2007
59. Mucke H, Yeates C, Norman P. Patent alert. Current Opin Invest Drugs. 2006;7(9):781-788